Table 2.

Multivariable Cox regression for rectal cancer specific survival amongst all patients with stage I – III rectal cancer treated with tri-modality therapy in California 2000–2007.

Characteristic		Neoadjuvant cohort N = 2833		Adjuvant cohort N = 1782
		HR (95% CI)	p Value	HR (95% CI)	p Value
Age (continuous – 10 year increment):		1.14 (1.05–1.24)	0.0028	1.18 (1.07–1.32)	0.0016
Sex:	Male	1.00 (reference)		1.00 (reference)
	Female	1.01 (0.81–1.25)	0.9598	0.91 (0.71–1.16)	0.4353
Race/Ethnicity:	Non-Hispanic White	1.00 (reference)		1.00 (reference)
	Non-Hispanic Black	1.34 (0.86–2.10)	0.1984	0.96 (0.54–1.69)	0.8764
	Hispanic	1.02 (0.76–1.37)	0.8733	1.04 (0.74–1.46)	0.8137
	Asian/Pacific Islander	0.82 (0.59–1.14)	0.2431	0.93 (0.64–1.36)	0.7189
Socioeconomic status:	1st – 2nd Quintile	1.00 (reference)		1.00 (reference)
	3rd Quintile	0.97 (0.73–1.30)	0.8400	1.32 (0.95–1.85)	0.0986
	4th – 5th Quintile	0.86 (0.67–1.12)	0.2603	1.07 (0.79–1.44)	0.6684
T stage:	0–1	1.00 (reference)		1.00 (reference)
	2	0.86 (0.50–1.48)	0.5789	1.89 (0.66–5.42)	0.2350
	3	1.53 (0.96–2.44)	0.0745	3.74 (1.38–10.17)	0.0097
	4	3.10 (1.87–5.14)	<0.0001	5.46 (1.92–15.59)	0.0015
N stage:	N0	1.00 (reference)		1.00 (reference)
	N1a	1.89 (1.36–2.61)	0.0001	1.14 (0.75–1.73)	0.5266
	N1b	2.18 (1.57–3.03)	<0.0001	1.54 (1.07–2.22)	0.0210
	N2a	3.75 (2.61–5.40)	<0.0001	2.60 (1.76–3.83)	<0.0001
	N2b	6.37 (4.40–9.23)	<0.0001	5.43 (3.71–7.93)	<0.0001
Nodes examined:	0–2	1.67 (1.10–2.54)	0.0168	1.74 (1.10–2.54)	0.0680
	3–5	1.77 (1.28–2.46)	0.0006	2.19 (1.48–3.23)	<0.0001
	6–8	1.68 (1.23–2.29)	0.0111	1.79 (1.26–2.53)	0.0010
	9–11	1.35 (0.97–1.88)	0.0747	1.30 (0.92–1.85)	0.1401
	12+	1.00 (reference)		1.00 (reference)